ABOUT – XENITRA
— XENITRA LIMITED

Growing the world’s best brands in Asia with authentic products and loyal customers

About Us

Xenitra Limited (ASX: XEN) connects premium Global FMCG Brands with high-growth Asian consumer markets.

Our growth strategy is based on two product-tailored sales channels: Pharmaceuticals and Web3 Commerce.

Explore More:

Our Two Core Segments

Our Experienced Board & Senior Management Team

Our Corporate Governance Procedures and Policies

ABOUT – TWO CORE ASSETS

Xenitra is focused on two core assets:

Please click on the blocks below to view details…

International Medicines and healthcare products distributed to consumers in China.

01 – Pharmaceuticals

Pharmaceuticals division fully established and selling

Summary

International medicines and healthcare products distributed to consumers in China through platform wholesale, B2B supply to shopfronts and owned digital shopfronts.

Product Profile

OTC and prescription medicines, and Food for Special Medical Purposes (FSMP), from global pharmaceutical brand partners.

Margin Profile

20-40%

Future Focus

More approved SKUs with reliable replenishment, diversified suppliers and channels, and a strategic offtake partnership with JD Health (in negotiation).

A$100m

JD Health – 3yr – Prescription Medicines

A$12m

Kangsheng – 3yr – OTC Medicines

A$1.43m

Pharma sales to date

200m+

JD Health customers

OTC medicines channel now operational

Hong Kong Fukang Trading Co. acquired (April 2026), enabling a fast start into the ecommerce channel with established sales, warehousing and team members experienced in cross-border OTC medicine sales in Greater China.

JD.com Storefront

An active OTC medicine shopfront on JD.com, China’s major B2C e-commerce platform, allowing an immediate and seamless commencement of sales.

Trademark and Warehouse infrastructure

Class 35 trademark registration plus warehouse logistics service, customer database, and on-hand inventory also acquired.

HK Pharma Licences established

Xenitra holds a Hong Kong pharmaceutical wholesale licence enabling cross-border OTC sales into China, plus OTC retail and prescription pharmaceutical licences.

$100m partnership: JD Health

A go-to-market strategy linking international suppliers through our Hong Kong operations to JD Health — China’s largest online healthcare platform.

Expanding Brand Partnerships

Product and brand portfolio includes Nestlé and Aptamil nutrition, Finacea, Naprogesic, Lixiana, Pien Tze Huang and HYLO.

Value Chain

Uniquely positioned to unlock value in the world’s second largest pharmaceutical market

Real world assets tied to smart contract framework for digitally engaged customers.

02 – Web3 Architecture

Web3 infrastructure — fully operational and in the market

Summary

End-to-end blockchain-enabled commerce and payment system, supported by authentication and a loyalty / rewards program driving customer willingness to pay.

Product Profile

FMCG products across all categories exclusive to Xenitra — piloted with EZZ Life Sciences and Biomiq.

Margin Profile

40-90 %

Future Focus

Rapidly expanding sales by onboarding new brands and increasing numbers of new distributor and end user customers.

A$2m

Web3 Sales · Apr-Oct 2026

780

Total Participants

355

Distributors

89

Wholesalers
Web3 Commerce

Web3 Commerce is the future of eCommerce

End-to-end blockchain-enabled commerce and payments. Xenitra has created a highly scalable, fractionalised and globally accessible business — minting OPAL tokens, building the Web3-powered XEN Shop, onboarding a network of hundreds of distribution partners and establishing the legal frameworks and token reserve fund.

Web1

Read

Browse information published on websites

Web2

Interact

Shop, communicate and earn platform-managed rewards

Web3

Own & Transact

Hold tokens in a wallet for authentication and rewards, or trade and transfer them

Web3 Infrastructure combined with RWA

Xenitra has created a highly scalable, fractionalized and globally accessible business

Where Xenitra Operates

Where Xenitra operates in Web3 Commerce

Physical product sales connected with an ongoing digital customer relationship.

ABOUT – BOARD & SENIOR MANAGEMENT
Head of China

Ms Zhao (Tracy) Zhang

VIEW PROFILE

Bachelor of Information Technology and Master of Accounting

Tracy is the commercial leader of Xenitra globally and is an accomplished professional in the Fast-Moving Consumer Goods (FMCG) sector. Throughout her career she has developed exceptional expertise in brand management, ecommerce and commercial operations. She is the architect behind the Huibeijia brand in China, successfully establishing a thriving network of over 400 stores nationwide and since 2023 has spearheaded significant commercial expansion within the Xenitra Sales and Marketing ecosystems in the Chinese market and internationally.

Non Executive Chairman

Dr Anthony Noble

VIEW PROFILE

Doctor of Philosophy, Master of Business Administration, Bachelor of Science

Anthony has extensive Board and management experience, including as CEO and Managing Director of Australian Biotherapeutics and The Calmer Co. Anthony worked for a decade building SFI-Health Group as Group Head of Innovation, Group Head of North Asia and was Managing Director of SFI-Research and SFI-Shineway (China). Anthony was part of the M&A team which acquired and integrated multiple companies including Flordis (Australia) Ginsana (Switzerland), Klaire Labs (USA), Prothera (USA), Complementary Prescriptions, (USA) and Potters (UK).

Anthony is Executive Director at Servatus Biopharmaceuticals Limited and leads their fast-growing Biomiq skincare brand.

Non-Executive Director

Mr Carl Hagon

VIEW PROFILE

Bachelor of Laws, Bachelor or Arts

Carl is an experienced board director with a strong background in governance, strategy, and commercial leadership. He brings a disciplined, outcomes focused approach to board oversight, informed by both senior commercial experience and a foundation in legal practice. In his legal career, Carl has advised clients across multiple sectors, working closely with executive teams on strategy formulation, business transformation, and growth initiatives.

Non-Executive Director

Mr Zoran Grujic

VIEW PROFILE

Bachelor of Commerce, Chartered Accountant

Mr Grujic is an accomplished board member and senior finance executive with over 20 years’ experience across ASX-listed entities and high-growth organisations. A Chartered Accountant and Graduate of the Governance Institute, he has held senior leadership roles across a diverse range of sectors, including financial services, FMCG, transport, equity markets, NDIS, not-for-profit organisations and SaaS Technology.

Non-Executive Director

Mr Li (Alex) Li

VIEW PROFILE

Bachelor of Tourism Management

Alex Li is a Director of Xenitra Limited and a prominent Australia–China tourism and hospitality leader. A Tourism Australia–awarded Aussie Specialist China Ambassador, he is Founder and President of V-Tour Travel Service Zhejiang (a top-three AU/NZ outbound wholesaler in China) and Chairman or Co-Founder of multiple tourism, hospitality and travel businesses across both countries.

ABOUT – CORPORATE GOVERNANCE

Corporate Governance

Constitution

NOV 2025

Corporate Governance Statement

AUG 2026